Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer
PRINCETON, N.J.-- July 11, 2018 (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) received approval from the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 11, 2018 Category: Drugs & Pharmacology Source Type: news

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma
In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib07/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news

Research Reveals Immunotherapy More Effective in Men
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough Revi...
Source: Asbestos and Mesothelioma News - July 3, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Oncolytic Virus Plus Ipilimumab Improves Responses in Advanced Melanoma
The combination of an oncolytic virus with ipilimumab yielded a significantly higher response rate vs ipilimumab alone in patients with advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Tremelimumab and Imfinzi Combo Effective for Mesothelioma
The novel immunotherapy drug mixture of tremelimumab and Imfinzi (durvalumab) produced encouraging results in the first phase II mesothelioma clinical trial examining this combination. The study, which included 40 mesothelioma patients in Italy, was published in the June 2018 edition of The Lancet Respiratory Medicine. Similar — or even more promising — results with this combination are expected to follow soon in the United States. “Results from this study are very promising,” investigator Dr. Luana Calabro, Siena University Hospital, told Asbestos.com. “This regimen also has shown a good safety profile. It warra...
Source: Asbestos and Mesothelioma News - June 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Supercharged’ Immunotherapy Could Target Mesothelioma Cell Protein
Standard mesothelioma treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy. These standard therapies do not offer a cure for people with mesothelioma, and that’s why scientists continue searching for better ways to treat the disease. Researchers at the Scripps Research Institute in Jupiter, Florida, have created a precision medicine approach that targets a protein on the surface of cancer cells to kill tumors. Although the drug was not specifically designed for mesothelioma patients, it may offer a more effective way to manage the disease in the future. The treatment is a type of imm...
Source: Asbestos and Mesothelioma News - June 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Researchers find combination can enhance ipilimumab immunotherapy
(University of Texas M. D. Anderson Cancer Center) Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers at The University of Texas MD Anderson Cancer Center report today in the Journal of Clinical Investigation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2018 Category: Cancer & Oncology Source Type: news

Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up
Dave LevitanJun 6, 2018After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Nivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma
Dave LevitanJun 5, 2018Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
(Tonic Life Communications USA) Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy ® ). Current data show an overall response rate of 38 percent following treatment with the combination of tilsotolimod and ipilimumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2018 Category: International Medicine & Public Health Source Type: news

No Reliable Predictors for Ipilimumab-Induced Hypophysitis No Reliable Predictors for Ipilimumab-Induced Hypophysitis
Study results highlight the need for endocrine monitoring of all patients receiving checkpoint inhibitor immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 29, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Risk Factors for Ipilimumab-Induced Hypophysitis Remain Unclear
(MedPage Today) -- Researchers recommend close monitoring of these patients (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 18, 2018 Category: Dermatology Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 2, 2018 Category: Health Management Authors: Ron Leuty Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 2, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news